Wellington Management Group LLP Offloads 3,111 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

2 min read | April 14, 2025 01:26 AM PDT | By Team Kalkine Media

Wellington Management Group LLP Offloads 3,111 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) — Image source: Shutterstock

Institutional Movements

During the fourth quarter of 2023, notable changes in institutional holdings occurred within Dyne Therapeutics, Inc. (NASDAQ:DYN). Wellington Management Group LLP reduced its position in the company by 7.5%, bringing their total holdings to 38,550 shares, valued at approximately $908,000. Simultaneously, other institutional investors adjusted their strategies. KBC Group NV increased its stake by a considerable amount, while E Fund Management Co. Ltd. also boosted its holdings. New investments came from several firms, including KLP Kapitalforvaltning AS and Magnetar Financial LLC. Institutional investors continue to represent the majority of Dyne Therapeutics' stock, with their collective holdings making up a significant portion of the company’s total shares.

Performance Overview

Dyne Therapeutics recently opened at a trading price of $7.04, far below its 52-week high of $47.45. This considerable fluctuation reflects the company's market volatility, with a market capitalization of $796.37 million. Despite facing a negative price-to-earnings ratio, the company's latest earnings report delivered a better-than-expected outcome, with a reported loss per share of ($0.88). This figure exceeded the consensus estimate, offering a glimpse of relative positive momentum despite ongoing challenges. The company's fiscal year earnings per share forecast remains in negative territory.

Insider Transactions

There have been notable insider transactions within Dyne Therapeutics. One such transaction saw insider Oxana Beskrovnaya selling 2,598 shares at an average price of $13.95. This sale, totaling a value of $36,242.10, reflects ongoing internal adjustments within the company. Despite the sale, insider ownership remains relatively high at 20.77%, suggesting continued confidence from those within the company, even with some reductions in individual holdings.

Company Profile

Dyne Therapeutics is at the forefront of biotechnology, focusing on developing therapeutics for genetically driven muscle diseases. The company’s FORCE platform aims to deliver disease-modifying treatments for a variety of conditions, including myotonic dystrophy type 1 and Duchenne muscular dystrophy. Positioned as a leader in the clinical-stage muscle disease field, Dyne Therapeutics continues to advance in this specialized niche, working toward transformative solutions for patients suffering from these rare and challenging conditions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.